Title |
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
|
---|---|
Published in |
Cancer Chemotherapy and Pharmacology, February 2010
|
DOI | 10.1007/s00280-010-1257-5 |
Pubmed ID | |
Authors |
Andrew H. Ko, Alan P. Venook, Emily K. Bergsland, R. Kate Kelley, W. Michael Korn, Elizabeth Dito, Brian Schillinger, Janet Scott, Jimmy Hwang, Margaret A. Tempero |
Abstract |
No standard of care exists for patients with metastatic pancreatic cancer following progression on first-line chemotherapy. Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 5% |
Italy | 1 | 3% |
Unknown | 36 | 92% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 8 | 21% |
Researcher | 8 | 21% |
Student > Ph. D. Student | 6 | 15% |
Student > Bachelor | 3 | 8% |
Student > Doctoral Student | 2 | 5% |
Other | 8 | 21% |
Unknown | 4 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 51% |
Agricultural and Biological Sciences | 7 | 18% |
Biochemistry, Genetics and Molecular Biology | 4 | 10% |
Nursing and Health Professions | 1 | 3% |
Psychology | 1 | 3% |
Other | 1 | 3% |
Unknown | 5 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#6,764,072
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#594
of 2,501 outputs
Outputs of similar age
#42,853
of 169,684 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#9
of 24 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,684 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.